|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 14 amino acid peptide near the carboxy terminus of human BCAS2.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||5 µg/ml|
|Western Blot (WB)||0.5-1 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is MCF7 cell lysate.
PA5-20905 can be used with blocking peptide PEP-1019.
BCAS2 was identified through differential display analysis as an mRNA species that was overexpressed in MCF7 and BT-20 breast cancer cell lines. The chromosomal region containing this gene, 1p13.3021, is amplified in these cells lines. BCAS2 is a transcriptional cofactor that enhances estrogen receptor-mediated gene expression, and directly interacts with the tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein level in the absence of DNA damage. Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but causes G2-M arrest in p53-null or -mutant cells; this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment of cancer.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.